<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>It was previously shown that <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>) patients transplanted with peripheral blood progenitor cells (PBPC) from HLA-C allele-matched donors had better clinical outcome when lacking the HLA-C-encoded KIR <z:chebi fb="0" ids="53000">epitope</z:chebi> C2 </plain></SENT>
<SENT sid="1" pm="."><plain>We investigated whether this holds true in other diseases and in HLA-C allele-mismatched patients </plain></SENT>
<SENT sid="2" pm="."><plain>Twenty-four <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), 39 <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>)/<z:mp ids='MP_0005481'>CML</z:mp>, and 34 <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo>/non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> patients received unrelated unmanipulated PBPC </plain></SENT>
<SENT sid="3" pm="."><plain>HLA matching was analyzed retrospectively (including DNA-based direct sequencing of HLA-C) </plain></SENT>
<SENT sid="4" pm="."><plain>Only in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>/<z:mp ids='MP_0005481'>CML</z:mp>, the C2 ligand was associated with impaired overall survival (OS, p &lt; 0.05) </plain></SENT>
<SENT sid="5" pm="."><plain>We next calculated the impact of donor/recipient HLA-C allele matching within the C1 and C2 groups </plain></SENT>
<SENT sid="6" pm="."><plain>Surprisingly, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>/<z:mp ids='MP_0005481'>CML</z:mp> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients with C2 ligands profited from HLA-C allele mismatching (OS, p &lt; 0.01), whereas in the C1 group, allele matching was beneficial (p &lt; 0.05) </plain></SENT>
<SENT sid="7" pm="."><plain>HLA-C allele mismatching in the C2 KIR ligand group was associated with lower TRM (OR 0.48, p &lt; 0.009) and lower relapse rate (OR 2.7 p &lt; 0.1) when compared to allele-matched C2 patients </plain></SENT>
<SENT sid="8" pm="."><plain>Thus, patients could be assigned to a low- and a high-risk group according to their C1/C2 ligand status and the HLA-C allele matching degree </plain></SENT>
<SENT sid="9" pm="."><plain>These data suggest that four-digit allele matching of HLA-C has differential effects dependent on the presence of C1 and C2 KIR <z:chebi fb="0" ids="53000">epitopes</z:chebi> in the patient </plain></SENT>
</text></document>